Allo Stem Cell Transplant for GATA2 Mutations
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 144 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, Chemotherapy, Radiation Therapy
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1717
- NCT Identifier
- NCT01861106
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.